Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression

Nature Genetics

Volumn 47, Issue 2, 2015, Pages 142-150

  Takeda, Haruna ^a,b   Wei, Zhubo ^c   Koso, Hideto ^a,d   Rust, Alistair G ^e   Yew, Christopher Chin Kuan ^a   Mann, Michael B ^a,c   Ward, Jerrold M ^a   Adams, David J ^e   Copeland, Neal G ^a,c   Jenkins, Nancy A ^a,c  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANKRD11 PROTEIN; APC PROTEIN; BETA CATENIN; CSNK2A1 PROTEIN; K RAS PROTEIN; MKL2 PROTEIN; MYO9A PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RNF43 PROTEIN; RSPO1 PROTEIN; RSPO2 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR SIN3A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZNF292 PROTEIN; CARRIER PROTEIN; DNA BINDING PROTEIN; NERVE PROTEIN; TRANSCRIPTION FACTOR; TRANSPOSON; ZFP292 PROTEIN, MOUSE; ZNF292 PROTEIN, HUMAN;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER GROWTH; CANCER STAGING; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DONOR SITE; EPIGENETICS; GASTROINTESTINAL TUMOR; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE INSERTION SEQUENCE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SLEEPING BEAUTY TRANSPOSON MUTAGENESIS; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ADENOCARCINOMA; ADENOMA; ANIMAL; C57BL MOUSE; COHORT ANALYSIS; COLORECTAL TUMOR; DISEASE COURSE; DNA SEQUENCE; DRUG SCREENING; EVOLUTION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GERMFREE ANIMAL; HIGH THROUGHPUT SEQUENCING; HUMAN; MALE; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; TRANSPOSON;

MUS;

ADENOCARCINOMA; ADENOMA; ANIMALS; BIOLOGICAL EVOLUTION; CARRIER PROTEINS; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA TRANSPOSABLE ELEMENTS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, TUMOR SUPPRESSOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUTAGENESIS, INSERTIONAL; MUTATION; NERVE TISSUE PROTEINS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926170118     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3175     Document Type: Article

References (62)

1. Kinzler, K.W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
2. Pinto, D. & Clevers, H. Wnt, stem cells and cancer in the intestine. Biol. Cell 97, 185-196 (2005).
3. Bos, J.L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689 (1989).
4. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
5. Wood, L.D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
6. Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664 (2012).
7. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
8. March, H.N. et al. Insertional mutagenesis identifes multiple networks of cooperating genes driving intestinal tumorigenesis. Nat. Genet. 43, 1202-1209 (2011).
9. Starr, T.K. et al. A transposon-based genetic screen in mice identifes genes altered in colorectal cancer. Science 323, 1747-1750 (2009).
10. Starr, T.K. et al. A Sleeping Beauty transposon-mediated screen identifes murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis. Proc. Natl. Acad. Sci. USA 108, 5765-5770 (2011).
11. Copeland, N.G. & Jenkins, N.A. Harnessing transposons for cancer gene discovery. Nat. Rev. Cancer 10, 696-706 (2010).
12. ARF-and p53-defcient mice identifes cancer genes and their collaborative networks. Cell 133, 727-741 (2008).
13. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
14. Tamura, A. et al. Megaintestine in claudin-15-defcient mice. Gastroenterology 134, 523-534 (2008).
15. Dunlop, M.G. et al. Common variation near CDKN1A, POLD3 and SHROOM2 infuences colorectal cancer risk. Nat. Genet. 44, 770-776 (2012).
16. de Lau, W. et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293-297 (2011).
17. Moser, A.R., Pitot, H.C. & Dove, W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322-324 (1990).
18. Guo, X. & Wang, X.F. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res. 19, 71-88 (2009).
19. Huang, W. et al. DAVID gene ID conversion tool. Bioinformation 2, 428-430 (2008).
20. Huart, A.S., MacLaine, N.J., Meek, D.W. & Hupp, T.R. CK1α plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J. Biol. Chem. 284, 32384-32394 (2009).
21. Meek, D.W. & Cox, M. Induction and activation of the p53 pathway: a role for the protein kinase CK2? Mol. Cell. Biochem. 356, 133-138 (2011).
22. Rotili, D. & Mai, A. Targeting histone demethylases: a new avenue for the fght against cancer. Genes Cancer 2, 663-679 (2011).
23. Huang, J. et al. p53 is regulated by the lysine demethylase LSD1. Nature 449, 105-108 (2007).
24. Pugh, T.J. et al. Medulloblastoma exome sequencing uncovers subtype-specifc somatic mutations. Nature 488, 106-110 (2012).
25. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010).
26. Kouzarides, T. Chromatin modifcations and their function. Cell 128, 693-705 (2007).
27. Zang, Z.J. et al. Exome sequencing of gastric adenocarcinoma identifes recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570-574 (2012).
28. Guan, B., Wang, T.L. & Shih Ie, M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 71, 6718-6727 (2011).
29. WAF1/CIP1 expression. Oncogene 30, 445-456 (2011).
30. Gur, G. et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 23, 3270-3281 (2004).
31. Laederich, M.B. et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J. Biol. Chem. 279, 47050-47056 (2004).
32. Powell, A.E. et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149, 146-158 (2012).
33. Segditsas, S. & Tomlinson, I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25, 7531-7537 (2006).
34. Singh, H. et al. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 3, e117 (2013).
35. Cowin, P.A. et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 72, 4060-4073 (2012).
36. Urick, M.E. et al. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 71, 4061-4067 (2011).
37. Xie, Z. et al. Zinc fnger protein ZBTB20 is a key repressor of α-fetoprotein gene transcription in liver. Proc. Natl. Acad. Sci. USA 105, 10859-10864 (2008).
38. Yuan, J., Luo, K., Zhang, L., Cheville, J.C. & Lou, Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384-396 (2010).
39. Noll, J.E. et al. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene 31, 2836-2848 (2012).
40. Li, J. et al. Myocardin-like protein 2 regulates TGFβ signaling in embryonic stem cells and the developing vasculature. Development 139, 3531-3542 (2012).
41. Medjkane, S., Perez-Sanchez, C., Gaggioli, C., Sahai, E. & Treisman, R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat. Cell Biol. 11, 257-268 (2009).
42. Muehlich, S. et al. The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1. Oncogene 31, 3913-3923 (2012).
43. Scharenberg, M.A., Chiquet-Ehrismann, R. & Asparuhova, M.B. Megakaryoblastic leukemia protein-1 (MKL1): increasing evidence for an involvement in cancer progression and metastasis. Int. J. Biochem. Cell Biol. 42, 1911-1914 (2010).
44. Yoshio, T., Morita, T., Tsujii, M., Hayashi, N. & Sobue, K. MRTF-A/B suppress the oncogenic properties of v-ras-and v-src-mediated transformants. Carcinogenesis 31, 1185-1193 (2010).
45. Koo, B.K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665-669 (2012).
46. Giannakis, M. et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 46, 1264-1266 (2014).
47. Murphy, M. et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13, 2490-2501 (1999).
48. Das, T.K., Sangodkar, J., Negre, N., Narla, G. & Cagan, R.L. Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene 32, 3184-3197 (2013).
49. Zender, L. et al. An oncogenomics-based in vivo RNAi screen identifes tumor suppressors in liver cancer. Cell 135, 852-864 (2008).
50. Bard-Chapeau, E.A. et al. Transposon mutagenesis identifes genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat. Genet. 46, 24-32 (2014).
51. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
52. Pérez-Mancera, P.A. et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486, 266-270 (2012).
53. Mann, K.M. et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 109, 5934-5941 (2012).
54. Lipkin, S.M., Naar, A.M., Kalla, K.A., Sack, R.A. & Rosenfeld, M.G. Identifcation of a novel zinc fnger protein binding a conserved element critical for Pit-1-dependent growth hormone gene expression. Genes Dev. 7, 1674-1687 (1993).
55. Fearon, E.R & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
56. Dupuy, A.J., Akagi, K., Largaespada, D.A., Copeland, N.G. & Jenkins, N.A. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436, 221-226 (2005).
57. Jackson, E.L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
58. Olive, K.P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004).
59. Takaku, K. et al. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 59, 6113-6117 (1999).
60. el Marjou, F. et al. Tissue-specifc and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186-193 (2004).
61. Quinlan, A.R. et al. Genome-wide mapping and assembly of structural variant breakpoints in the mouse genome. Genome Res. 20, 623-635 (2010).
62. Brett, B.T. et al. Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors. PLoS ONE 6, e24668 (2011).